PEPVERAAUTHENTIC HIGH-QUALITY PEPTIDES
SIGN IN
Tirzepatide
CUT · II

Tirzepatide

Second of its order. For those denied the third.

From / per milligram
$50$5.0/mg · 10MG
Sizes available
10mg · 15mg · 20mg · 30mg · 40mg · 60mg · 100mg
Lab certificate (COA)
Supplier-published sample
Compare 1 suppliers ↓View test certificate →

· Research-grade only · Not for human consumption · 21+ ·

What is it

FDA-approved weight-loss and type 2 diabetes therapy (Mounjaro / Zepbound). Suppresses appetite and steadies glucose. Weekly subcutaneous injection.

Mechanism · Dual GLP-1 + GIP receptor agonist. SURMOUNT and SURPASS Phase 3. FDA approved 2022 / 2023.

Who

Best for. Not for.

Best for

  • BMI ≥30, or BMI ≥27 with comorbidities (Zepbound label).
  • Type 2 diabetes (Mounjaro label).
  • Plateau or nausea-intolerant on semaglutide monotherapy.
  • Comfortable with a weekly subcutaneous protocol.

Not for

  • Personal or family history of MTC or MEN-2 syndrome (FDA boxed warning).
  • History of pancreatitis.
  • Pregnancy, nursing, or planned pregnancy.
  • Type 1 diabetes or elevated DKA risk.
  • Severe gastroparesis.
  • Renal impairment (creatinine clearance <30).
What it does

Mechanism, dose, ramp, risk.

Mechanism
Dual-receptor agonist (GLP-1 + GIP). Approved analogue (Mounjaro / Zepbound).Source · PEPVERA editorial
Target dose
10 mg / week by week 8.Source · PEPVERA editorial
Ramp
10 weeks. Begin at 2.5 mg.Source · PEPVERA editorial
Risks
Anxiety, nausea, gastrointestinal disturbance. Titrate slowly.Source · PEPVERA editorial
Alternatives

Compared to its siblings.

★ Currently viewing

Tirzepatide

FDA-approved weight-loss and type 2 diabetes therapy (Mounjaro / Zepbound). Suppresses appetite and steadies glucose. Weekly subcutaneous injection.

Pros

  • · FDA approved with a deep SURMOUNT/SURPASS dataset, unlike retatrutide.
  • · Greater fat-loss potency than semaglutide (~21% vs ~14%).
  • · Better lean-mass preservation than semaglutide (SURMOUNT-5).
  • · Weekly injection vs liraglutide's daily burden, with higher efficacy.

Cons

  • · Lower Phase 2 weight loss than retatrutide (~21% vs ~24%).
  • · No glucagon arm; lower resting energy expenditure than retatrutide.
  • · Shorter long-term safety record than semaglutide or liraglutide.
  • · No pediatric (12+) approval, unlike liraglutide.

Retatrutide

Triple receptor adds the glucagon arm. Phase 2 head-to-head delivers a deeper cut.

Pros

  • · ~24% Mean weight loss in Phase 2 vs ~21% for tirzepatide.
  • · Glucagon arm lifts resting energy expenditure.

Cons

  • · Still Phase 2. No FDA approval yet.
  • · Long-term safety profile not yet established.

See Retatrutide →

Semaglutide

GLP-1 only. Older incretin with the longest real-world safety record.

Pros

  • · 10+ Years FDA approved. The most validated entry.
  • · Stable supply and broader insurance coverage.

Cons

  • · Lower fat-loss potency: about -14% vs -21% head-to-head.
  • · Trails tirzepatide on lean-mass preservation (SURMOUNT-5).

See Semaglutide →

Liraglutide

First-generation daily injection with the longest pediatric safety history.

Pros

  • · FDA pediatric (12+) approval (Saxenda 2020).

Cons

  • · Daily injection burden.
  • · Lower efficacy. About 8% mean weight loss.

See Liraglutide →

How we verify

COA per supplier

Published, in-house, or shipment-time

Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.

→ How we verify suppliers→ Refund policy
Fat lossMetabolicappetite-suppressantGLP-1GIPPopularresearch-only
Suppliers

Compare 7 suppliers

SupplierPriceCOAShips
Royal PeptidesUS$50$5.00/mg · 10mgSample COA published3 days
Royal PeptidesUS$75$5.00/mg · 15mgSample COA published3 days
Royal PeptidesUS$110$5.50/mg · 20mgSample COA published3 days
Royal PeptidesUS$150$5.00/mg · 30mgSample COA published3 days
Royal PeptidesUS$190$4.75/mg · 40mgSample COA published3 days
Royal PeptidesUS$255$4.25/mg · 60mgSample COA published3 days
Royal PeptidesUS$380$3.80/mg · 100mgSample COA published3 daysOut of stock
❄ COLD-CHAIN · 5–9 DAYS

Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.

Before you begin

Risk

Anxiety, nausea, gastrointestinal disturbance. Titrate slowly. These pass with discipline. They do not pass with bravado.

Source · PEPVERA editorial

Discipline

10 weeks. Begin at 2.5 mg.

Source · PEPVERA editorial

Wellness

Hydrate. Eat protein. Sleep eight. Hold a dose for at least two weeks before ascending.

Anti-patterns

  • · Do not pair with stimulants late in the day.
  • · Do not break the cycle without a planned taper.
  • · Do not exceed the dose to chase a deeper sleep response.

Crisis

If the ramp triggers severe anxiety, anhedonia, or persistent gastrointestinal disturbance, stop. Resume after two weeks at half the prior dose. The discipline is the slow climb.

Dosing protocol

Week 1–2

0.25 mg / wk

Baseline ramp

Week 3–4

0.5 mg / wk

Hold, observe

Week 5–8

1.0–2.0 mg / wk

Ascend

Week 9–12

10 mg / week by week 8.

Terminus

Reconstitution

Draw 20 units.

1 mg = 0.20 mL at 5.00 mg/mL. 10.0 doses per vial.

cut · II · Royal Peptides

Tirzepatide · 10mg